The next generation of antiemetics for the management of postoperative nausea and vomiting.

Journal Article (Journal Article;Review)

Postoperative nausea and vomiting (PONV) afflict approximately 30% of patients overall and up to 80% of high-risk patients after surgery. Optimal pharmacological prophylaxis of PONV is challenging as it necessitates the consideration of PONV risk, drug efficacy, and potential adverse effects. Despite significant advances in our understanding of the pathophysiology and risk factors of PONV, its incidence has remained largely unchanged. Newer antiemetics have been introduced that may have improved safety profiles, longer duration of action, and better efficacy. This review aims to summarize the recent developments pertaining to these new agents and their potential application toward the management of PONV.

Full Text

Duke Authors

Cited Authors

  • Tan, HS; Dewinter, G; Habib, AS

Published Date

  • December 2020

Published In

Volume / Issue

  • 34 / 4

Start / End Page

  • 759 - 769

PubMed ID

  • 33288125

Electronic International Standard Serial Number (EISSN)

  • 1878-1608

Digital Object Identifier (DOI)

  • 10.1016/j.bpa.2020.11.004


  • eng

Conference Location

  • Netherlands